Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688050's Return-on-Tangible-Asset is ranked better than 74.68% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.76
vs SHSE:688050: 7.78
Eyebright Medical Technology (Beijing) Co (SHSE:688050) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Eyebright Medical Technology (Beijing) Co Return-on-Tangible-Asset Related Terms
Eyebright Medical Technology (Beijing) Co Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eyebright Medical Technology (Beijing) Co Return-on-Tangible-Asset Chart
Eyebright Medical Technology (Beijing) Co Annual Data
SHSE:688050 vs ISRG, BDX, MDLN: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, Eyebright Medical Technology (Beijing) Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eyebright Medical Technology (Beijing) Co Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Eyebright Medical Technology (Beijing) Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Eyebright Medical Technology (Beijing) Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 10.02% mean?
Eyebright Medical Technology (Beijing) Co (SHSE:688050) has a Return-on-Tangible-Asset of 10.02% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Eyebright Medical Technology (Beijing) Co and its competitors. This is near median its historical median of 9.57. According to the industry distribution chart, Eyebright Medical Technology (Beijing) Co ranks #216 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 25.3%.
Is Eyebright Medical Technology (Beijing) Co's Return-on-Tangible-Asset too high?
Eyebright Medical Technology (Beijing) Co's current Return-on-Tangible-Asset of 10.02% is near median its 10-year median of 9.57. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.76. Eyebright Medical Technology (Beijing) Co's value of 10.02% is 1218.4% above this industry median. Based on the distribution chart, Eyebright Medical Technology (Beijing) Co ranks #216 out of 853 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Eyebright Medical Technology (Beijing) Co has a GF Score™ of 80/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Eyebright Medical Technology (Beijing) Co's Return-on-Tangible-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Eyebright Medical Technology (Beijing) Co ranks #216 out of 853 companies for Return-on-Tangible-Asset. This puts Eyebright Medical Technology (Beijing) Co in the upper half of its industry. The industry median Return-on-Tangible-Asset is 0.76. Eyebright Medical Technology (Beijing) Co's value of 10.02% is 1218.4% above this benchmark. While the company's 10-year median is 9.57 vs. the industry median of 0.76, Eyebright Medical Technology (Beijing) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.76, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eyebright Medical Technology (Beijing) Co's current Return-on-Tangible-Asset of 10.02% is 1218.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Eyebright Medical Technology (Beijing) Co and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eyebright Medical Technology (Beijing) Co's current Return-on-Tangible-Asset is 10.02%, which is near median its own 10-year median of 9.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eyebright Medical Technology (Beijing) Co stock overvalued right now?
Based on GuruFocus' analysis, Eyebright Medical Technology (Beijing) Co (SHSE:688050) is currently considered Possible Value Trap. The stock's GF Value™ is ¥114.17, compared to a current price of ¥40.46 — trading 64.6% below its estimated fair value. The current Return-on-Tangible-Asset is 10.02%, which is near median its 10-year median of 9.57 and 1218.4% above the Medical Devices & Instruments industry median of 0.76. Eyebright Medical Technology (Beijing) Co's overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Eyebright Medical Technology (Beijing) Co (SHSE:688050), the current Return-on-Tangible-Asset is 10.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eyebright Medical Technology (Beijing) Co (SHSE:688050) Overvalued in 2026?
Based on GuruFocus' analysis, Eyebright Medical Technology (Beijing) Co stock appears to be undervalued.
The current stock price of ¥40.46 is trading 64.6% below its estimated GF Value™ of ¥114.17.
GuruFocus considers Eyebright Medical Technology (Beijing) Co to be Possible Value Trap.
Key valuation signals for SHSE:688050:
Return-on-Tangible-Asset: 10.02% (near median its 10-year median of 9.57)
GF Value™: ¥114.17 vs. price of ¥40.46 (64.6% below fair value)
Industry Position: 1218.4% above the Medical Devices & Instruments median (#216 of 853)
No single metric tells the full story. See the SHSE:688050 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eyebright Medical Technology (Beijing) Co Ltd is engaged in research and development, production, sales and related services of ophthalmic medical devices. The company's product range includes Intraocular Lens; IOL Delivery System; Ophthalmic Instruments; Other Products; Literature; and Expert Interview.
80GF Score
Get the complete analysis for SHSE:688050
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688050 has been successfully added to your 
